VTVT - vTv Therapeutics azeliragon flunks in mid-stage alzheimer's and diabetes study

vTv Therapeutics (VTVT) slumps 38% after-hours after announcing that its Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition relative to placebo.The trail included 43 people. The azeliragon treated group (n=21) had a 1.8 point decline from baseline in ADAS-cog14 compared to a placebo (n=22) decline of 0.35.These differences were not statistically significant.Azeliragon was generally well-tolerated.

For further details see:

vTv Therapeutics azeliragon flunks in mid-stage alzheimer’s and diabetes study